Literature DB >> 1760762

Treatment of Mycobacterium paratuberculosis infection in ruminants.

G St-Jean1, A D Jernigan.   

Abstract

Paratuberculosis is a chronic, debilitating, fatal condition that usually is clinically undetectable until the onset of copious diarrhea. Paratuberculosis is caused by an acid-fast organism, M. paratuberculosis. Successful eradication of paratuberculosis depends on the early detection of infected animals, thereby allowing removal of carrier animals from the herd. Treatment for paratuberculosis is therefore rarely indicated or undertaken; however, treatment may be considered for animals of exceptional genetic value or companion animals. Antimicrobials reviewed in this article for the treatment of paratuberculosis include isoniazid, rifampin, streptomycin, amikacin, clofazimine, and dapsone. Treatment of paratuberculosis requires daily medication for extended periods and results in palliation of the disease rather than a definitive cure. The treatment for paratuberculosis recommended by the authors is isoniazid at 20 mg/kg administered orally every 24 hours for the rest of the animal's life. When the animal has acute onset of diarrhea, rifampin at 20 mg/kg every 24 hours is also administered orally. In severe, imminently life-threatening cases, an aminoglycoside should be administered concurrently for 3 to 8 weeks. This protocol (isoniazid, rifampin, and an aminoglycoside) will help ensure that Mycobacteria organisms are sensitive to at least two of the antibiotics. Rifampin treatment can be discontinued if clinical signs of paratuberculosis disappear and the cost of therapy is judged excessive. The combined therapeutic approach has been used in three animals, and the results are presented in this article. Because isoniazid, rifampin, and some aminoglycosides are not approved for use in food animals in the United States of America, the meat or milk from treated animals should not be used for human consumption.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1760762     DOI: 10.1016/s0749-0720(15)31085-9

Source DB:  PubMed          Journal:  Vet Clin North Am Food Anim Pract        ISSN: 0749-0720            Impact factor:   3.357


  9 in total

Review 1.  Mycobacterium avium subsp. paratuberculosis in Veterinary Medicine.

Authors:  N B Harris; R G Barletta
Journal:  Clin Microbiol Rev       Date:  2001-07       Impact factor: 26.132

2.  Development of a firefly luciferase-based assay for determining antimicrobial susceptibility of Mycobacterium avium subsp. paratuberculosis.

Authors:  S L Williams; N B Harris; R G Barletta
Journal:  J Clin Microbiol       Date:  1999-02       Impact factor: 5.948

3.  Resolution of Crohn's disease and complex regional pain syndrome following treatment of paratuberculosis.

Authors:  J Todd Kuenstner; William Chamberlin; Saleh A Naser; Michael T Collins; Coad Thomas Dow; John M Aitken; Stuart Weg; Grzegorz Telega; Kuruvilla John; David Haas; Torsten M Eckstein; Maher Kali; Christine Welch; Thomas Petrie
Journal:  World J Gastroenterol       Date:  2015-04-07       Impact factor: 5.742

4.  A 60-day probiotic protocol with Dietzia subsp. C79793-74 prevents development of Johne's disease parameters after in utero and/or neonatal MAP infection.

Authors:  Robert E Click
Journal:  Virulence       Date:  2011-07-01       Impact factor: 5.882

Review 5.  Paratuberculosis.

Authors:  C Cocito; P Gilot; M Coene; M de Kesel; P Poupart; P Vannuffel
Journal:  Clin Microbiol Rev       Date:  1994-07       Impact factor: 26.132

6.  Successful treatment of asymptomatic or clinically terminal bovine Mycobacterium avium subspecies paratuberculosis infection (Johne's disease) with the bacterium Dietzia used as a probiotic alone or in combination with dexamethasone: Adaption to chronic human diarrheal diseases.

Authors:  Robert E Click
Journal:  Virulence       Date:  2011-03-01       Impact factor: 5.882

7.  Susceptibility of Mycobacterium avium sbsp paratuberculosis to monensin sodium or tilmicosin phosphate in vitro and resulting infectivity in a murine model.

Authors:  Gordon W Brumbaugh; R Bruce Simpson; John F Edwards; Dwayne R Anders; T D Thomson
Journal:  Can J Vet Res       Date:  2004-07       Impact factor: 1.310

8.  A Potential 'Curative' Modality for Crohn's Disease---Modeled after Prophylaxis of Bovine Johne's Disease.

Authors:  Robert E Click
Journal:  Mycobact Dis       Date:  2012-05-31

9.  Enrofloxacin and macrolides alone or in combination with rifampicin as antimicrobial treatment in a bovine model of acute Chlamydia psittaci infection.

Authors:  Annette Prohl; Markus Lohr; Carola Ostermann; Elisabeth Liebler-Tenorio; Angela Berndt; Wieland Schroedl; Michael Rothe; Evelyn Schubert; Konrad Sachse; Petra Reinhold
Journal:  PLoS One       Date:  2015-03-13       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.